

0040-4039(93)E0351-J


Enantiopure *N*-Acyl dihydropyridones as Synthetic Intermediates. An Asymmetric Synthesis of Solenopsin A.

Daniel L. Comins* and Nezha Radi Benjelloun

Department of Chemistry
 North Carolina State University, Raleigh, NC 27695-8204

Abstract: The *trans*-piperidine alkaloid, (-)-solenopsin A, was prepared in seven steps from readily available 4-methoxy-3-(triisopropylsilyl)pyridine in 43% overall yield.


The addition of organometallics to chiral 1-acylpyridinium salt **1** gives *N*-acyl-2-alkyl-2,3-dihydro-4-pyridones **2** with high diastereoselectivity.^{1,2} The dihydropyridones **3**, prepared from **2** in one step, are useful chiral building blocks for various alkaloids.^{2,3} Recently, we developed a synthesis of enantiopure 2-alkylpiperidines using this methodology.^{2c} With a practical asymmetric synthesis of 2-alkylpiperidines in hand, the preparation of enantiopure *trans*-2,6-dialkylpiperidines was investigated using an approach that combined our chemistry with Beak's *N*-Boc-piperidine α -lithiation methodology.⁴ The plan was to prepare enantiopure *N*-Boc-piperidines **4**, which would be subjected to Beak's lithiation/alkylation to give the desired *trans*-2,6-dialkylpiperidines **5** and **6** in an asymmetric fashion. To this end, an enantioselective synthesis of solenopsin A (**7a**) was initiated.



Solenopsin A is one of several alkaloids present in the venom of the red fire ant, *Solenopsis invicta*.^{5,6} The fire ant alkaloids exhibit hemolytic, insecticidal, and antibiotic activity⁶, and have generated much synthetic

activity.^{7,8} There have been five enantioselective syntheses of solenopsin A (7a) or B (7b) to date requiring 7 to 13 synthetic steps from readily available material.⁸ We report here a 7-step, highly stereocontrolled synthesis of (-)-solenopsin A from 4-methoxy-3-(triisopropylsilyl)pyridine.


The synthetic plan called for the conversion of an *N*-Boc-2-alkyl-2,3-dihydro-4-pyridone **8** to an intermediate *N*-Boc-piperidine **4**. Multi-step reductions of *N*-acyl-2,3-dihydro-4-pyridones to *N*-acylpiperidines



have been reported in the literature. Kunz^{3a} and Waldmann⁹ have reported similar 3-step reductions involving L-Selectride 1,4-reduction, dithioacetal formation, and Raney nickel desulfurization. We recently reported a 2-step reduction by first converting the dihydropyridone to a 4-chloro-1,2-dihydropyridine using the Vilsmeier reagent; subsequent catalytic reduction gave the piperidine derivative.^{2c} This procedure generates HCl, however, and is not compatible with *N*-Boc groups. Since **9a** was not a viable intermediate, we decided to pursue a related 2-step reduction via a vinyl triflate, i.e. **9b**.

The 1-acylpiperidinium salt **1b** was prepared in situ from 4-methoxy-3-(triisopropylsilyl)pyridine¹ and the chloroformate of readily available (-)-*trans*-2-(α -cumyl)cyclohexanol¹⁰ ((-)-TCC). A THF solution of undecylmagnesium bromide was added dropwise (1.5 h) to the chiral salt at -78 °C in toluene to give dihydropyridone **10** on acidic workup in 95% crude yield and 90% de. Purification by radial PLC (silica gel, EtOAc/hexanes) provided an 85% yield of pure diastereomer **10**. Treatment of **10** with NaOMe/MeOH and then 10% HCl gave a 90% yield of deprotected dihydropyridone **11** $[[\alpha]_{\text{D}}^{25} + 237$ (c 1.3, CHCl_3)] along with recovered (-)-TCC (95%). The *N*-Boc-dihydropyridone **12** was prepared from **11** in 97% yield using di-*tert*-butyldicarbonate, triethylamine, and DMAP in THF (RT, 14 h). The enone portion of **12** was completely reduced via the vinyl triflate **13**. Deprotonation of **12** with NaHMDS and enolate trapping with *N*-(5-chloro-2-pyridyl)triflimide¹¹ provided a 76% yield of **13**. Catalytic reduction^{2a} of **13** (H_2 , PtO_2 , Li_2CO_3 , EtOH) gave a quantitative yield of *N*-Boc-piperidine **14** $[[\alpha]_{\text{D}}^{26} - 25.1$ (c 1.58, CHCl_3)]. Lithiation using Beak's conditions (*sec*-BuLi, TMEDA, THF, -78 °C)⁴ and alkylation with Me_2SO_4 gave *trans*-piperidine **15**, which on treatment

with HCl/Et₂O at reflux (1.0 M, 7.5 h) provided a 77% yield of pure solenopsin A·HCl as white crystals, mp 141-142 °C; [α]_D²⁴ - 7.6 (*c* 0.5, CHCl₃) [lit.^{8a,c} mp 146 °C; [α]_D²³ - 7.6 (*c* 0.7, CHCl₃)]. The spectral properties of our (-)-solenopsin A·HCl were in agreement with reported data.^{8e,12}



Acknowledgement. We wish to express appreciation to the National Institutes of Health (Grant GM 34442) for support of this work. NMR and mass spectra were obtained at NCSU instrumentation laboratories, which were established by grants from the North Carolina Biotechnology Center and the National Science Foundation (Grant CHE-8417529).

References and Notes

- Comins, D. L.; Goehring, R. R.; Joseph, S. P.; O'Connor, S. *J. Org. Chem.* **1990**, *55*, 2574.
- (a) Comins, D. L.; Dehghani, A. *Tetrahedron Lett.* **1991**, *32*, 5697. (b) Comins, D. L.; Hong, H. *J. Am. Chem. Soc.* **1991**, *113*, 6672. (c) Comins, D. L.; Hong, H.; Salvador, J. M. *J. Org. Chem.* **1991**, *56*, 7197. (d) Comins, D. L.; LaMunyon, D. H. *J. Org. Chem.* **1992**, *57*, 5807. (e) Al-awar, R. S.; Joseph, S. P.; Comins, D. L. *Tetrahedron Lett.* **1992**, *33*, 7635.

3. For the synthesis of non-racemic dihydropyridones **3** using the aza Diels-Alder reaction, see: (a) Pfrengle, W.; Kunz, H. *J. Org. Chem.* **1989**, *54*, 4261. (b) Waldmann, H.; Braun, M.; Drager, M. *Angew. Chem. Int. Ed. Engl.* **1990**, *29*, 1468. (c) Hattori, K.; Yamamoto, H. *J. Org. Chem.* **1992**, *57*, 3264 and references cited therein.
4. (a) Beak, P.; Lee, W. K. *Tetrahedron Lett.* **1989**, *30*, 1197. (b) Beak, P.; Lee, W. K. *J. Org. Chem.* **1990**, *55*, 2578. (c) Beak, P.; Lee, W. K. *J. Org. Chem.* **1993**, *58*, 1109.
5. (a) MacConnell, J. G.; Blum, M. S.; Fales, H. M. *Tetrahedron* **1971**, *27*, 1129. (b) Jones, T. H.; Blum, M. S.; Fales, H. M. *Tetrahedron* **1982**, *38*, 1949.
6. Blum, M. S. *Alkaloidal Ant Venoms: Chemistry and Biological Activities, Bioregulators for Pest Control*; ACS Symposium Series 276; American Chemical Society: Washington, D.C., 1985; pp. 393-408.
7. For syntheses of racemic solenopsins (A and B), see: (a) Fuji, K.; Ichikawa, K.; Fujita, E. *Chem. Pharm. Bull.* **1979**, *27*, 3183. (b) Matsumura, Y.; Maruoka, K.; Yamamoto, H. *Tetrahedron Lett.* **1982**, *23*, 1929. (c) Sakane, S.; Matsumura, Y.; Yamamura, Y.; Ishida, Y.; Maruoka, K.; Yamamoto, H. *J. Am. Chem. Soc.* **1983**, *105*, 672. (d) Carruthers, W.; Williams, M. J.; Cox, M. T. *J. Chem. Soc., Chem. Commun.* **1984**, 1235. (e) Nakazono, Y.; Yamaguchi, R.; Kawanishi, M. *Chem. Lett.* **1984**, 1129. (f) Mundy, B. P.; Bjorklund, M. *Tetrahedron Lett.* **1985**, *26*, 3899. (g) Takahashi, K. K.; Kurita, H.; Ogura, K.; Iida, H. *J. Org. Chem.* **1985**, *50*, 4368. (h) Yamaguchi, R.; Nakazono, Y.; Matsuki, T.; Hata, E.; Kawanishi, M. *Bull. Chem. Soc. Jpn.* **1987**, *60*, 215. (i) Wasserman, H. H.; Rusiecki, V. *Tetrahedron Lett.* **1988**, *29*, 4977. (j) Nagasaka, T.; Hayashi, H.; Kumakawa, M.; Sakamoto, M. *Heterocycles* **1989**, *29*, 2157. (k) Comins, D. L.; Weglarz, M. A. *J. Org. Chem.* **1991**, *56*, 2506.
8. (a) Grierson, D. S.; Royer, J.; Guerrier, L.; Husson, H.-P. *J. Org. Chem.* **1986**, *51*, 4475. (b) Taber, D. F.; Decker, P. B.; Fales, H. M.; Jones, T. H.; Lloyd, H. A. *J. Org. Chem.* **1988**, *53*, 2968. (c) Ukaji, Y.; Watai, T.; Sumi, T.; Fujisawa, T. *Chem. Lett.* **1991**, 1555. (d) Kotsuki, H.; Kusumi, T.; Inoue, M.; Ushio, Y.; Ochi, M. *Tetrahedron Lett.* **1991**, *32*, 4159. (e) Jefford, C. W.; Wang, J. B. *Tetrahedron Lett.* **1993**, *34*, 2911. (f) Also see: Hill, R. K.; Yuri, T. *Tetrahedron* **1977**, *33*, 1569.
9. Waldmann, H.; Braun, M. *J. Org. Chem.* **1992**, *57*, 4444 and references cited therein.
10. (a) Comins, D. L.; Salvador, J. M. *Tetrahedron Lett.* **1993**, *34*, 801. (b) Comins, D. L.; Salvador, J. M. *J. Org. Chem.* **1993**, *58*, 4656 and references cited therein.
11. Comins, D. L.; Dehghani, A. *Tetrahedron Lett.* **1992**, *33*, 6299.
12. ¹³C NMR data for **7a** (free base): (75 MHz, CDCl₃) δ 50.81, 45.80, 34.08, 32.99, 31.88, 30.79, 29.79, 29.62, 29.31, 26.44, 22.64, 21.22, 19.56, 14.06. For comparison with reported data, see reference 8e.

(Received in USA 29 October 1993; accepted 29 November 1993)